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ABSTRACT
Objective:
To study the Thyroid Stimulating Receptor Antibodies (TSHRAb) level in
various thyroid Disease by analyzing the TSH receptor antibodies level and
comparing it with other thyroid antibodies and to analyze the importance of its
estimation in  various Thyroid Diseases with Hyperthyroidism or Hypothyroidism.
Design:
70 patients of various thyroid disease admitted in the period between 2008-
2010 were included in the study. After classifying the patients on the basis of
anatomical, physiological and pathological diagnosis, serum levels of thyroid-
stimulating hormone receptor antibodies (TSHRAbs) were assayed along with
antithyroperoxidase antibodies and antithyroglobulin antibodies. Clinical features like
eye  signs,  tremors  and  thyromegaly  were  assessed.  Results  were  tabulated  and
analyzed.
Results:
Out of the 70 patients included in this study, 29 patients were found to have
elevated TSHRAb levels. Elevated TSHRAb levels correlated with serum alkaline
phosphatase levels, hyperthyroidism, Graves’ disease and ophthalmopathy. Out of 60
patients with multinodular goiter, 25 had elevated levels of TSHRAbs, which
indicated the association of autoimmune thyroid disease (Graves’ disease) with
multinodular goiter.
Conclusion:
The levels of TSHRAb grossly parallel the degree of hyperthyroidism, the
grade  of  thyromegaly  and  presence  of  ophthalmopathy.  Elevated  levels  of  Serum
Alkaline phosphatase along with TSHRAb in hyperthyroidism may be taken as a
marker for severity of Graves’ disease.
TABLE OF CONTENTS
Chapter 1 Introduction and objectives………………………….1
Chapter 2 Review of literature………………………………….4
Chapter 3 Research and methodology………………………... 26
Chapter 4 Results and discussion…………………………….. 28
Chapter 5 Conclusion………………………………………… 50
References………………………………………………………………51
LIST OF TABLES
Table 1 Correlation of antibodies to various thyroid Antigens with
anatomical diagnosis……......………………………………………29
Table 2 Correlation of serum levels of various thyroid antibodies with
functional states of thyroid………………………………………….31
Table 3 Correlation of levels of antibodies with pathological diagnosis……33
Table 4 Mean age and levels of thyroid hormones and thyrotropin in
TSHRAb positive patients……………....………………………….35
Table 5 Correlation of thyromegaly with THSRAb levels………………….36
Table 6 Correlation of mean values of various antibodies with thyroid
functional status…………………………………………………….38
Table 7 Correlation of mean values of TSHRAb levels with pathological
diagnosis……………………………………………………………39
Table 8 Correlation of TSHRAb levels with ATG and AMA………………41
Table 9 Correlation of Eye signs with TSHRAb levels……………………..43
Table 10 Correlation of SAP and Serum Calcium with TSHRAb levels…….44
Chapter 1
Introduction and objectives
_____________________________________________________________________
11. INTRODUCTION AND OBJECTIVES
1.1   INTRODUCTION
Detection of thyroid antibodies can be helpful in establishing the diagnosis of
autoimmune thyroid disease.
All autoimmune thyroid diseases share common immunological markers.1
Antibodies against TSHR represent only one family of thyroid antibodies. Others
include TPO antibodies and antithyroglobulin antibodies.
Historically, thyrotoxicosis in Graves’ disease has been known to be caused by
the action of THSR stimulation antibodies. Also, it was believed that these antibodies
are never found in other diseases affecting the thyroid gland.2 However, TSHR
antibodies (TSHRAbs) have been found in about 20 % of other thyroid diseases.3
The nomenclature for the thryotropin receptor antibodies (TRABs) is complex
and largely dependent on the assay used to detect these antibodies in serum. The
assays that measure the displacement of radio-labelled TSH from its receptor by
serum  immunoglobulins  detect  TRAbs  regardless  of  their  functional  activity.  These
antibodies have also been termed as TSH-binding Inhibitory Immunoglobulins
(TBIIs).4 TSH-stimulating  antibodies  (TSAbs)  are  essentially  the  cause  of
hyperthyroidism  in  Graves’  disease.  TSH-blocking  antibodies  (TBAbs)  are  the
causative factor for atrophic auto-immune thyroiditis.5 However, in vitro, the
TSHRAbs might act as a stimulator or blocker depending upon other factors.6
2THSR antibodies are pathogenically capable of activating or blocking TSH
receptor function as demonstrated by the occurrence of trans-placentally transmitted
hyperthyroidism or hypothyroidism in the fetus of mothers with high enough levels of
stimulating or blocking TSHR antibodies in circulation.
Pathogenic antibodies could be reviewed as the ideal marker for the diagnosis
and management of the corresponding autoimmune disease.
Indication for TRAb determination include the following :
? The detection or exclusion of autoimmune hyperthyroidism and its
differentiation from disseminated autonomy of the thyroid gland. The presence
of TRAb indicates that the patients thyrotoxicosis is of autoimmune etiology
rather  than  due  to  toxic  nodular  goiter.  Because  the  aim  of  treatment  for
Graves disease may differ from the treatment of other forms of thyrotoxicosis,
an initial TRAb determination is clearly of value.
? Monitoring  the  therapy  of  Graves  disease  patients  and  prediction  of  relapse,
thereby constituting an important decision-making aid in the management of
the treatment. TRAb levels tend to fall during antithyroid drug therapy for
Graves  disease.  Low  levels  or  the  absence  of  TRAb  after  a  course  of  drug
treatment may indicate disease remission, and therefore the withdrawal of
therapy can be considered.
? TRAb measurement during the last trimester of pregnancy. Because TRAb are
IgG-class antibodies, they cross the placenta and can cause neonatal thyroid
disease. The measurement of TRAb during pregnancy in patients with history
3of thyroid disease is therefore important in assessing the risk of thyroid disease
in the neonate.
With this background, this study was conducted with an aim to study
the TSH receptor antibody level in various thyroid diseases.
1.2 Objectives :
To study the TSH receptor antibodies level in various Thyroid Disease by
analysing the TSH receptor antibodies level and comparing it with other thyroid
antibodies and to analyze the importance of its estimation in Autoimmune Thyroid
Diseases with Hyperthyroidism or Hypothyroidism
Chapter 2
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42. REVIEW OF LITERATURE
2.1 ANTI-TSH RECEPTOR ANTIBODIES IN CLINICAL PRACTICE
      Autoimmune thyroid diseases are the more prevalent organ-specific
autoimmune  disorders  in  humans.   They  encompass  a  wide  spectrum  of  clinical
presentations, with hyperthyroid Graves’ disease at one end and atrophic myxedema
at the other.  Whether Graves’ disease and lymphocytic thyroiditis represent different
aspects  of  the  same  disease  or  different  diseases  remains  unclear.   Autoimmune
thyroid diseases share common immunologic markers-mono nuclear cell infiltration
of the thyroid-and circulating antithyroid antibodies, the specificities of which might,
in part, account for the diversity of these diseases.  Autoantibodies against the
thyroid-stimulating hormone receptor (TSH receptor antibodies, (TSHR-Ab) represent
only one family of thyroid autoantibodies.  Others include antithyroperoxidase (TPO-
Ab), the former antithyroid microsomal antibodies, antithyroglobulin, and the recently
identified anti-sodium/iodide symporter antibodies.  Historically, TSHR-Ab have
been associated with hyperthyroid Graves’ disease.7  Indeed, contrary to the other
antithyroid antibodies, TSHR-Ab are pathogenic, capable of activating or blocking
TSH receptor functions, as demonstrated by the occurrence of transplacentally
transmitted hyperthyroidism or hypothyroidism in the fetus of mothers with high
enough levels of circulating stimulating or blocking TSHR-Ab.
Pathogenic antibodies could be viewed as the ideal marker for the diagnosis
and management of the corresponding autoimmune disease.  The various conditions
5discussed in this article that could benefit from the assay of TSHR-Ab include the
following.
Graves’ disease
TSHR-Ab at diagnosis of hyperthyroid Graves’ disease
Diagnostic value
Severity marker
An aid to the choice of treatment
TSHR-Ab and the management of antithyroid drug (ATD) treatment
TSHR-Ab and ablative treatments
Special conditions
Graves’ disease and pregnancy
Graves’ disease in children and adolescents
Extrathyroidal manifestations of Graves’ disease
Graves’ disease and thyroid carcinoma
    Autoimmune hypothyroidism
Prevalence of TSHR-Ab in autoimmune thyroiditis
Clinical usefulness of TSHR-Ab assays
Transient transplacental neonatal hypothyroidism
Spontaneous remission from autoimmune hypothyroidism
6Depending on the clinical setting, the determination of either stimulating or
blocking  TSHR-Ab  is  discussed.   The  presence  of  TSHR-Ab  is  the  hallmark  of
Graves’ disease.  Nevertheless, TSHR-Ab may be detected in other conditions,
indicating the possible association of Graves’ disease with other thyroid diseases.
2.2 AN OVERVIEW OF THE TSHR-Ab ASSAYS
      Currently, two approaches are used to detect TSHR-Ab.  One approach is
based on the competition between the antibody and TSH for binding to the TSH
receptor (TSH-binding inhibitory immunoglobulin (TBII).  The other approach is
based on the changes in the functional status of the receptor induced by the anitbody-
receptor interaction.  Both approaches are biologic methods.  The competitive assay is
commercially available using8 bovine TSH and solubilized porcine TSH receptor.
The functional assay measures the production/accumulation of cAMP by stably
transfected chinese hamster ovary cells with the human TSH receptor.  The
competitive assay is not indicative of any functinal activity of the antibody.  On the
contrary, only functional assays can identify whether the antibody in agonistic
(thyroid-stimulating antibody (TSAb) or antagonsitic [TSH stimulation blocking
antibody  (TSHAb)].   These  TSBAb  may  be  present  in  the  same  patients  with
stimulating antibodies, the effect of which is also inhibited, the overall activity being
the algebraic sum of the two levels of activity.
     Because competitive and functional assays do not necessarily measure the
same type of interaction, it is not surprising that there is no continuous correlation
between the results of the two assays.  Nevertheless, sera with high levels of TBII are
usually also positive in stimulation assays, except when TSBAb are predominant.
7      Methodologic improvements  have recently been proposed, taking advantage
of use of the recombinant human TSH receptor.  Autoantibody binding to membrane-
expressed TSH receptor can be detected by fluorescence9 with good sensitivity or
immunocytochemistry.10 Immunoprecipitation  of in vitro translated TSH receptor
might represent a fruitful approach ; however, persisting difficulties associated with
the large-scale production of recombinant human TSH receptor of suitable
conformation and glycosylation still limit the development of direct and specific
immunodetection of TSHR-Ab.  Other approaches in progress are attempting to
delineate functional epitopes on the TSH receptor and may lead to assays able to
distinguish stimulating antibodies from blocking antibodies.  In the meantime, a TBII
assay with improved senstivity has been recently established that uses immobilized
solubilized recombinant human TSH receptor and either I-labeled or
chemiluminescent bovine TSH.11 This new assay must be evaluated on a larger scale.
Improvements in fucntional assays have also been proposed that would allow less
cumbersome techniques with higher throughput.
Clearly, there is a need for standardization of the techniques and reagents used, and
cooperative multilaboratory quality control studies need to be performed.  Multicenter
studies are also needed to evaluate the prevalence and levels of TSHR-Ab among
patients from various populations because geographic or ethnic differences might
account for divergences in the usefulness of TSHR-Ab assays.
82.3 GRAVES’ DISEASE AND TSHR-Ab ASSAYS
Diagnosis of Hyperthyroid Graves’ Disease
Diagnostic Value of the TSHR-Ab
The prevalence of TSHR-Ab at diagnosis of hyperthyroid Graves’ disease
ranges from 70% to 100%.  .  The initial TSAb activity averages 200% to 300% as
expressed in percent increase of basal cAMP production.  These relatively low levels
of  TSHR-Ab  activity  in  routine  assays  are  consistent  with  the  result  of  quantitative
studies indicating that serum from the average patient with Graves’ disease contains
TSHR-Ab concentration much lower than 1 to 5 µg/ml, whereas TPO-Ab may
reach concentrations of 1 mg/mL.  Moreover, as mentioned previously,
optimization of the sensit ivity of the TSHR-Ab assays is  still  in progress.   With
current methods, the proportion of patients with undetectable TSHR-Ab before
treatment averages 10%.12 In the study by Ilicki and co-workers,12 in  all  of  the
initially TSHR-Ab-negative patients, TBII and TSAb became detectable 3 months
after radioiodine therapy.  On the basis that TSHR-Ab-negative cases usually present
with smaller goiters and lower levels of thyroid hormones and radioiodine thyroid
uptake, it has been proposed that they might correspond to an early stage of the
disease.  Such cases could be characterized by more marked lymphocytic infiltration
of  the  thyroid  than  in  TSHR-Ab positive  case, which could implicate local cytokine
production in thyroid regulation.
      Because the presence of TSHR-Ab is specific for Graves’ disease, TSHR-Ab
positivity in patients with nodular or multinodular toxic goiter is indicative of the
combination of the two diseases.13 This occurrence is common in areas with mild
9iodine deficiency but can be recognized chemically only in the case of associated
features of Graves’ ophthalmopathy.
TSHR-Ab as a Marker of Severity
It is common observation that the level of  TSHR-Ab grossly parallels the degree
of hyperthyroidism as assessed by the serum levels of thyroid homones.16, 34, 43, 56
TSHR-Ab levels, by no means, can be considered to merely reflect the agonist-effect
relationship in vivo; however, such quantitative correlation is generally observed in
the transplacental model of fetal hyperthyroidism, which suggests the existence, in the
diseased thyroid of the patients, of alterations capable of modulating the nature or the
expression of the interaction of TSHR-Ab with thyroid cells.  TSHR-Ab levels more
likely reflect the intensity or duration of the intrathyroidal inflammatory autoimmune
reactions.
      In general, good agreement has been observed between TSHR-Ab and thyroid
volume in untreated patients with Graves’ disease.14 Whether the controversial
thyroid growth immunoglobulins have any relevance to the process of autoimmune
goitrogenesis remains unsettled. Rieu and co-workers15 found that the volume of both
hyperplastic and nodular tissue was correlated with TSHR-Ab in untreated patients
with typical Graves’ disease, confirming the growth stimulation potential of these
antibodies on any thyroid tissue.
TSHR-Ab as an Aid to the Choice of Treatment
     Several studies have assessed the usefulness of TSHR-Ab level determination
at diagnosis as an aid to to the management of patients.  Because the basic therapeutic
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alternative for hyperthyroid patients with Graves’ disease is medical, with a high risk
of relapse, or radical/ablative, it has been questioned whether the assay of TSHR-Ab
contributes to the allocation of the patient to the optimum treatment arm.  There is no
simple answer to that question, and it seems that TSHR-Ab determination is only one
of the indicators to identify patients who are likely to achieve remission without
ablative treatment.
     The more recently reported studies16 performed in various parts of the world
with very different iodine environments suggest that, when considered alone, TSHR-
Ab positivity or titre before treatment is significantly correlated or uncorrelated to the
post-ATD treatment outcome.  The initial TSHR-Ab  status has not had high enough
positive and negative predictive values for remission or relapse after completion of
ATD treatment to support, by itself, the treatment decision in most patients.
Nevertheless, taking into account the titre of TSHR-Ab and other indicators such as
age, gender, thyroid volume, the severity of hyperthyroidism, and possibly, the
presence of ophthalmopathy, subgroups of patients can be identified with a high or
low risk of relapse  In a study by Michelangeli and colleagues17 in Australia of 104
patients  followed  up  for  15  months  to  5  years,  the  relapse  rate  in  patients  with  an
intial TBII greateer than 60 U/L was 68% as compared with the average figure of
54% for the whole cohort.  In a study by Benker and  co-workers,18 45% of the
patients  with  high  levels  of  TBII  were  euthyroid  after  3  weeks  of  ATD  therapy  as
compared with 67% of patients who were negative or borderline for TSHR-Ab.  In
that study of the initial response to ATD treatment, other predictors such as goiter
size, urinary iodine excretion, and the severity of hyperthyroidism were as significant,
or even more, than the titre of TSHR-Ab.
11
      Although it is not necessay for the diagnosis of Graves’ disease, except in
some  cases  of  multinodular  goiter,  initial  TSHR-Ab  measurement  is  useful  as  a
marker of disease severity and may, in combination with other clinical indicators
contribute to the treatment decision.
2.4 TSHR-Ab And The Management of ATD Treatment
Because recent surveys of treatment policies have shown that nondestructive
therapy for hyperthyroid Graves’ disease remains the preferred modality in most
centers outside North America, the optimization of ATD therapy remains a valid topic
of  clinical  research  to  find  ways  to  minimize  the  relapse  rate.   Many studies  of  the
dose and duration of ATD treatment have been reported.  One question merits
consideration: could the determination of TSHR-Ab during ATD treatment contribute
to the adaptation of the treatment plan to each case?  Is it of benefit for the patient to
monitor the level of TSHR-Ab during treatment?  Two types of studies have been
performed.  In one type, the evolution of the level of TSHR-Ab, that is, the rate of fall
of TSHR-Ab, has been used as an indicator for treatment withdrawal or correlated
with the relapse rate.18  In the other type of study using a fixed predetermined dose
and duration of ATD treatment, the TSHR-Ab status at the end of the drug course has
been correlated with posttreatment outcome.
      Studies of the first type have found that the rate of fall of TSHR-Ab (TBII)
during ATD treatment is predictive of subsequent outcome.  In the series reported on
by Michelangeli,17 73% of TBII-negative patients remitted compared with 28% of
TBII-positive patients, after 12 months of treatment; corresponding percentages were
12
70% and 17% after 18 months.  TBII values measured at 6 months of treatment were
not discriminant.
      The duration of the course of ATD can be adapted to the TSHR-Ab status.  In
a study by Edan and co-workers,8 44 of 64 patients tested every 3 months in whom
therapy was stopped when TSHR-Ab (TSAb) became negative were maintained on
ATD for an average of 9 months (range, 3 to 18 months).  Among these patients, the
relapse rate was 41% in comparision with a rate of 92% for the patients who remained
TSAb-positive after 18 months of treatment. The data reported by Cho and co-
workers, who also compared fixed and adapted durations of ATD administration, are
similar.  Detailed analysis of these studies suggests that, even in the case of early
disappearance of TSHR-Ab, the duration of ATD treatment should be 9 to 12 months
to minimize the risk of relapse.
      The  studies  investigating  TSHR-Ab  assays  at  the  end  of  an  ATD  course  of
predetermined duration have been analyzed by Feldt-Rasmussen and colleagues.28
This analysis clearly shows the value and limitations of the TSHR-Ab predictions.
TSHR-Ab-negative patients had 65% less risk of relapsing than TSHR-Ab-positive
patients.  By increasing the cut-off level for TSHR-Ab positivity, it is possible to
obtain  a  predictive  value  of  a  positive  test  of  almost  1.00  but  at  the  expense  of
lowering the predictive value of a negative test.19 In the study by Vitti,20 relapse was
observed in 97.5% of the patients with high TSHR-Ab and in 41.4% of patients with
low levels.
      In contrast to the data reported by Hashizume and co-workers,21 several
studies have indicated that the administration of levothyroxine during and after
13
withdrawal of ATD treatment does not improve the outcome nor affect the evolution
of TSHR-Ab levels.22 Such trials have been based on the theoretic concepts of (1) the
potential thyroidal immunosuppressive effect of ATD, leading to the use of a high
dosage of the medication, and (2) the beneficial effect of “letting the thyroid test” by
preventing any rise in TSH.
2.5 TSHR-Ab and Ablative Treatments
Radioiodine Treatment
      Radioiodine  efficiency  does  not  seem  to  be  dependent  on  TSHR-Ab  status;
however, a recent report identified a correlation between pretreatment TSHR-Ab level
(both TBII and TSAb) and postirradiation outcome.  There was an inverse
relationship between the initial TBII level and the reduction in thyroid volume per
megabecquerel retained.  Also, residual hyperthyroidism was significantly correlated
with higher pretreatment TSHR-Ab levels, and initial TSAb levels were higher in
patients who became euthyroid when compared with patients who became
hypothyroid.  Initial TSHR-Ab levels seem to contribute to the thyroid resistance to
radioiodine therapy.  Supportive data have been reported by Chiovato and co-
workers.23 This resistance could result from increased I turnover or protection of
thyroid tissue viability through reduced apoptosis or better regeneration.
      Radioiodine treatment is associated with a transient increase in the level of
TSHR-Ab and, in some cases, the appearance of blocking TSHR-Ab.  The extent to
which the postirradiation thyroid function evolution is dependent on changes in
TSHR-Ab levels or activity is currently under study.  Early transient hypothyroidism
14
might be associated with blocking TSHR-Ab, whereas the recovery of euthyroidism
might be associated with an increase in stimulating antibodies. It is premature to
recommend the routine assay of TSHR-Ab in the follow-up of radioiodine treatment.
Surgical Treatment
      Subtotal thyroidectomy is effective when residual hormone output is
insufficient to maintain hyperthyroid levels.  TSHR-Ab determination has no practical
routine usefulness in this setting except when it is of interest to study the evolution of
circulating TSHR-Ab after removal of the thyroid (see further on), and when
postsurgery outcome of thyroid function is partly related to TSHR-Ab status.  After
surgery, TSHR-Ab decline and become undetectable in most patients within 6 to 9
months.24 The disappearance of TSHR-Ab from the circulation within a few weeks in
many patients is in line with the concept of the target organ being the main site of
autoantibody production; however this situation is not always true.  Whether
postoperative TSHR-Ab levels correlate with residual thyroid volume has not been
studied thoroughly; however, it has been suggested that thyroidectomy could
modulate immunologic activity of the disease.
      The outcome after thyroidectomy is mainly dependant on the residual volume
of the gland.  Many retrospective studies have shown a correlation between
postopertive recurrence of hyperthyroidism and the lack of decline of TSHR-Ab
during ATD therapy before operation or the persistence of TSHR-Ab after operation.
With the current trend toward more extensive removal of thyroid tissue in an attempt
to prevent recurrences, TSHR-Ab determination is of no help in the management of
patients, except in the perspective of subsequent pregnancy.
15
Special Conditions
Graves’ Disease and Pregnancy
      Graves’ disease is common in women of reproductive age, with the prevalence
rate of current or previous disease ranging from  0.5% to 1%.  Hyperthyroid Graves’
disease is estimated to occur at a rate of 0.5 to 2 per 1000 pregnancies.  Although
uncommon during pregnancy, this association has gained much attention as a complex
situation with potential maternal and fetal complications.  The prevention of this
complication illustrates the benefits accrued from medical knowledge and expert
multidisciplinary management.  The main characteristics of Graves’ disease during
pregnancy are as follows:
1.  The diagnosis of hyperthyroidism may be overlooked because mild
clinical signs and symptoms may resemble the manifestations
associated with pregnancy.
2.  For reasons not completely elucidated, autoimmune hyperthyroid
Graves’ disease spontaneously improves during pregnancy so that, in a
majority of patients, ATD treatment can be markedly reduced or even
stopped.  Nevertheless, in approximately 10% of  patients,  no
improvement    is observed, which requires a higher dosage of agents.
3.  The fetal thyroid is affected by ATD and TSHR-Ab, which both cross
the placental barrier     readily, contrary to maternal thyroid hormones.
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4.  Because TSHR-Ab production may persist for several years after
radical radioiodine or surgical treatment of hyperthyroid Graves’
disease, euthyroid or T4-substituted women previously treated
radically for Graves’ disease may still have the risk of exposing the
fetus to TSHR-Ab.
      Although ATD treatment during pregnancy carries the risk of fetal
hypothyroidism and goiter if not appropriately managed, feto-neonatal
hyperthyroidism is observed in 2% to 10% of pregnancies in mothers with current or
previous Graves’ disease owing to maternal TSHR-Ab.  It represents a serious
condition  with  a  16%  neonatal  mortality  rate  and  the  risk  of  intrauterine  death,
stillbirth, and skeletal developmental abnormalities-including craniosynostosis.  Feto-
neonatal hyperthyroidism occurs in association with the highest levels of maternal
TSHR-Ab25, therefore, it is a predictable disease.  Recently, the following guidelines
for measurment of TSHR-Ab during pregnancy have been proposed in the American
and European literature.
In  the  woman  with  antecedent  Graves’  disease  in  remission  after  ATD
treatment, the risk for feto-neonatal hyperthyroidism is negligible, and systematic
measurement of TSHR-Ab is not necessary.  Thyroid function should be evaluated
during pregnancy to detect an unlikely but possible recurrence.  In that case, TSHR-
Ab assay is mandatory.
In the women with antecedent Graves’ disease previously treated with
radioiodine or thyroidectomy and regardless of the current thyroid status
(euthyroidism with or without thyroxine substitution), TSHR-Ab should be measured
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early in pregnancy to evaluate the risk for fetal hyperthyroidism.  If the level is high,
careful monitoring of the fetus is mandatory for the early detection of signs of thyroid
overstimulation (pulse rate > 170 bpm, impaired growth rate, oligoamnios, goiter).
Cardiac echography and measurement of circulatory velocity may be confirmatory.
Ultrasound measurements of the fetal thyroid have been defined from 20 weeks’
gestational age but require a well-trained operator, and thyroid visibility may be
hindered owing to fetal head position.  Color Doppler ultrasonography is helpful in
evaluating thyroid hypervascularization.  Because of the potential risks of feto-
neonatal hyperthyroid cardiac insuffiency and the lack of easy measurement of the
degree of hyperthyroidism in the mother because of previous thyroid ablation, it may
be appropriate consider direct diagnosis in the fetus.  Fetal blood sampling through
cordocentesis is feasible as early as 25 to 27 weeks’ gestation with less than 1%
adverse effects (fetal bleeding, bradycardia, infection, spontaneous abortion, in utero
death) when performed in experienced centers. ATD administration to the mother
may be considered to treat the fetal hyperthyroidism even though such treatment  does
not yet benefit from wide experience.
In the woman with concurrent hyperthyroid Graves’ disease, regardless of
whether it has preceded the onset of pregnancy, ATD treatment should be adjusted to
keep free T4 in the high-normal range to prevent fetal hypothyroidism.  TSHR-Ab
should be measured at the beginning of the last trimester, especially if the required
ATD dosage is high.  If the TSHR-Ab assay is negative or the level low, feto-neonatal
hyperthyroidism is unlikely.  If antibody levels are high (TBII is greater than or equal
to 40 U/L or TSAb is greater than or equal to 300%), evaluation of the fetus for
hyperthyroidism is mandatory.  In this condition, there is usually a fair parallelism
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between maternal and fetal thyroid function such that monitoring the ATD dosage
according to the mother’s thyroid status is appropriate for the fetus.  In some cases in
which a high dose of ATD (>300 mg/d of propylthiouracil (PTU) or > 20 mg/d of
methimazole) is necessary, there is a risk of goitrous hypothyroidism in the fetus,
which  might  be  undistinguishable   from  goitrous  Graves’  disease.   The  correct
diagnosis  relies  on  the  assay  of  fetal  thyroid  hormones  and  TSH,  which  allows  for
optimal treatment.
In the woman who has previously given birth to a newborn with
hyperthyroidism, TSHR-Ab assay should be performed early in the course of
pregnancy.
When the TSHR-Ab level is significant during late pregnancy, TSHR-Ab must
be determined in cord blood in the newborn and then sequentially at 7- to 10-day
intervals for 2 to 4 months to monitor the duration and dose of ATD treatment.
      Although the bioassay for stimulating antibody is theoretically preferred to the
radiocompetitive assay, several factors should be considered when selecting an assay.
1. When simpler stimulatory bioassays or direct epitope-specific assays become
available, the practical advantages of the current commercial radiocompetitive
assays may be overridden.
2. In the experience of most clinicians, assays for TBII serve the purpose of
detecting transplacental feto-neonatal hyperthyroidism satisfactory, with the
exception  of  the  occurrence  of  natural  stimulatory  antibodies  devoid  of
activity in the radiocompetitive assay.
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3. A recent report suggests that there may be a shift from stimulating to blocking
activity of TSHR-Ab during pregnancy with a decrease in TSAb despite
unchanged TBII levels.  This fascinating observation should be explored
further.
      The author suggests use of the radiocompetitive method for routine detection
of  TSHR-Ab.   The  minority  of  patients  with  positive  sera  should  be  tested
subsequently in stimulation and blocking bioassay.
Graves’ Disease in Children and Adolescents
      Because hyperthyroid Graves’ disease is usually more severe in younger
patients, thyroid ablation is the most common therapeutic option.  Long-term
remission rates in children and adolescents are usually less than 30% to 40% and
much lower in prepubertal (17%) than pubertal children(30%).26 Predictors of early
remission include age, body mass index, heart rate, goiter size, serum T4 and T3
concentrations, platelet count, the TSHR-Ab titer at diagnosis, changes in goiter size,
and the time required for serum T4 and T3 concentration to normalize during ATD
treatment.32 In the previously mentioned collaborative study of 191 patients, because
of insufficient data, it was not possible to include TSHR-Ab values in the multivariate
analysis, precluding their evaluation as an independent predictor of outcome.
Nevertheless, the low remission rate and the uncertainity regarding ATD treatment in
this age group support the use of any method capable of identifying patients who will
benefit from radical treatment.  The predictive significance of the new-generation
assays of TSHR-Ab is expected to be even more pertinent in children and adolescents
than in adults.
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Extrathyroidal Manifestations of Graves’ Disease
      Graves’ ophthalmopathy, pretibial myxedema, and acropachy are observed in
60%, 2% to 5%, and less than 1% of patients with Graves’ disease, respectively.
Pretibial myxedema, often observed after radioiodine treatment and usually presenting
with ophthalmopathy, is always associated with high titers of TSHR-Ab, although the
link between the two is not understood.  In patients who have pretibial myxedema of
an unusual type, an assay of TSHR-Ab is useful for confirmation of the diagnosis.
      Graves’ ophthalmopathy is clearly not caused by anti- TSHR-Ab as shown in
the materno-feto-neonatal model of transplacental hyperthyroidism; however, there is
an association between TSHR-Ab and Graves’ ophthalmopathy in epidemiologic and
longitudinal studies.27 The expression of the TSH receptor by activated retroocular
fibroblasts suggests an implication of anti-TSHR-Ab or TSH receptor-specific T cells
in this disease.  The epitopes involved in retroocular autoreactivity could be non
specific or neutral because sera from patients negative for classic TSHR-Ab have
been shown to react with the TSHR receptor in Western blotting. In clinical practice,
the detection of TSHR-Ab is useful in the patient with suspected euthyroid Graves’
ophthalmopathy as one of the abnormalities characterizing subclinical thyroid disease.
TSHR-Ab are detected in 32% to 40% of patients who have euthyroid Graves’
disease.  In some patients, the presence of TSHR-Ab may be the only detectable
abnormality.
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Graves’ Disease and Thyroid Carcinoma
      Thyroid carcinoma occus with higher than expected frequency (4% to 7%) and
greater severity in patients with Graves’ disease.  TSHR-Ab can stimulate the
function and growth of differentiated thyroid cancer metastases and anigiogenesis in
the  thyroid.   In  a  recent  publication,  among 21  patients  with  thyroid  carcinoma and
Graves’ disease.  TSAb were present in all but one of the patients in whom recurrence
developed.28 Although no comparative study is available, it is likely that the presence
of TSHR-Ab in such patients is a significant risk factor.
2.6 TSHR-Ab AND AUTOIMMUNE HYPOTHYROIDISM
      Although stimulating TSHR-Ab are the hallmark of Graves’ disease, blocking
TSHR-Ab are present in some patients with autoimmune primary hypothyroidism.
Indeed, the pathogenetic role of TSBAb in autoimmune thyroiditis is suggested not
only by their prevalence but by their capacity to induce neonatal transient
hypothyrodism.
Prevalence of TSHR-Ab in Autoimmune Thyroidits
      Based on the extensive review published in 1995 by Ducornet and co-
workers,29 the prevalence of TBII ranges from 0% to 44% in goitrous thyroiditis
(mean, 9%) and from 0% to 54% (mean, 21%) in atrophic thyroiditis (primary
myxedema).  For TSBAb, the corresponding figures are 0% to 44% (mean 12%) and
0% to 62% (mean 33%), respectively.  Clearly, the prevalence of TSBAb is higher in
nongoitrous than goitrous autoimmune thyroiditis and in overt than subclinical
hypothyroidism or euthyroid thyroiditis.30 Also,  the  prevalence  of  TSBAb  seems
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much greater in Asian than Caucasian populations.  In contrast, TSBAb are
uncommon in children.
Clinical Use of TSHR-Ab Assay in Patients with Autoimmune Hypothyroidism
Indentification of Transient Transplacental Neonatal Hypothyroidism
The hypothesis that maternally transmitted antithyroid anitbodies are the cause
of familial congenitial hypothyroidism was first proposed by Beierwaltes and co-
workers in 1959.  It became progressively  evident through subsequent studies that
maternal antithyroglobulin and anithyroperoxidase antibodies are not pathogenic to
the fetus.  In 1980 Matsuura and co-workers31 reported the first cases of transient
neonatal  hypothyroidism,  owing  to  maternal  TSBAb.   Since  then,  the  prevalence  of
TBII in newborns with congenital hypothyroidism has been estimated to range form
0.8% to 38%. In the mothers of hypothyroid newborns, TBII are detected in 5% and
TSBAb in 4%.  On the whole, transient anitbody-related neonatal hypothyroidism
amounts to 1% of all causes of congenital hypothyroidism.  Current assay methods do
not permit the routine systematic detection of TSBAb in neonatal blood spots.
Nevertheless, transient transplacental neonatal hypothyroidism is as predictable as
feto-neonatal hyperthyroidism by the assay of maternal TBII and, if positive, by an
assay  of  TSBAb  during  the  last  trimester.   Epidemiologic  data  suggest  that  this
screening is indicated in women with atrophic primary myxedema.  There is a
correlation between the severity of the hypothyroidism as assessed by thyroid
function at birth and the degree of development of the inferior femoral epiphysis and
the inhibitory activity of TSBAb, and thyroid uptake of radioiodine or pertechnetate is
suppressed in this condition.  Vigorous substitutive treatment of the neonate is
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mandatory as early as possible when hypothyroidism has been expected or diagnosed
at neonatal screening.  The newborn should be monitored to detect disappearance of
TSBAb at 7- to 15- day intervals.  Substitutive treatment is generally maintained for
several weeks or months after the 1.5- to 2- month period when the TSBAb assay has
become negative.
Spontaneous Remission from Autoimmune Hypothyroidism
      In the few series reported, reversibility of autoimmune hypothyroidism has
been observed in 0% to 24% of patients.  Takasu and co-workers found TSBAb in
10% of patients with goitrous autoimmune thyroiditis and in 25% of patients with the
atrophic form.  During a maximum follow-up period of 11 years, 15 of the 21 patients
with blocking antibodies became negative.  Among them, six patients remained
euthyroid after thyroxine treatment withdrawal.  In contrast, in the six TSBAb-
positive patients with atrophic thyroiditis, blocking anitbodies and hypothyroidism
persisted for the whole follow-up.32 Measurement of TSBAb is not a specific marker
of spontaneous recovery from hypothyroidism because disappearance of the anitbody
is not necessarily parallel to the disappearance of hypothyroidism.  Moreover,
systematic screening for spontaneous recovery from hypothyroidism does not seem
justified based on epidemiologic grounds nor is it cost-effective.
TSHR-Ab and Atypical Thyroid Autoimmune Patterns
      Fluctuating Thyroid Function.  Spontaneous evolution of hyperthyroid
Graves’ disease to hypothyroidism has been characterized.  In many cohorts with
long-term follow-up of 10 to 15 years, this evolution occurs in 2.1% to 2.8% of
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patients treated with ATD.33 Different mechanisms may be involved.  Although the
development of destructive autoimmune thyroiditis has been observed, the presence
of TSBAb is demonstrated in 20% to 40% of cases.34 TSBAb  may  result  from  a
conversion of the bioactivity of TSAb or may coexist with TSAb at the time of
hypothyroidism.  TBII are usually detectable.  In most cases, hypothyroidism, is
definitive; thus, the presence of TBII is not an indicator of subsequent normalization.
      More than 60 cases of fluctuating thyroid function have been reported, most of
which have been associated with the spontaneous evolution of hypothyroidism to
hyperthyroidism.29 In a few cases, cycles of transition from hypothyroidism to
hyperthyroidism or the converse have been observed.35,36 Determination of the
TSHR-Ab, TBII, and stimulating/blocking antibodies is useful in an attempt to
characterize these unusual anecdotal cases, although there is not always a
concordance between thyroid status and the net bioactivity of TSHR-Ab.
2.7 Hypothyroid Graves’ Disease.
Hypothyroid Graves’ disease is defined as the development of Graves’
ophthalmopathy in a hypothyroid subject.  The association of infiltrative
ophthalmopathy with primary hypothyroidism is rare.37 In a recently reported series
of five patients, all were positive for TSAb but not for TSBAb.  Thyroid function
fluctuated in four patients.  All of the patients had high levels of antithyroglobulin and
antithyroperoxidase antibodies.  In these cases, TSHR-Ab assay confirmed the
association of Graves’ disease and autoimmune thyroiditis.
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2.8 Painless Thyroiditis.
TSHR-Ab are uncommon in postpartum of thyroiditis; thus, they are not
predictable for recovery.  In the sporadic forms of painless thyroiditis. TSHR-Ab are
detected  in  6%  to  20%  of  cases.   In  some  case  reports,  determination  of  TSHR-Ab
and sometimes of TSBAb has been useful for diagnosis. In the few instances
associated with hypothyroidism, the disappearance of TSBAb justifies a substitutive
treatment withdrawal trial.
Chapter3
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3. RESEARCH METHODOLOGY
3.1  Place  :
Department of Endocrine Surgery
 Rajiv Gandhi Government General Hospital Chennai
 All study patients were inpatients in ward 135.
3.2 Patients and Methods :
70 patients of various thyroid disease admitted between 2008-2010 were
included in the study.
3.2.1 Criteria for inclusion :
All patients who had clinical hypothyroidism or hyperthyroidism or thyroid
nodules with biochemical evidence of antibody positivity were included in the study.
3.2.2 Investigations :
The following investigations were done for all the patients
- Complete Haemogram
- Thyroid function tests (T3,T4,TSH,FT3,FT4)
- Anti-TPO antibodies
- Anti thyroglobulin antibodies
- TSHR antibodies
- Serum Calcium
- Serum Alkaline Phosphatase
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3.2.3 Consent :
 Informed consent was obtained from patients prior to inclusion in the study.
3.2.4 Ethical committee approval:
The ethical committee of Madras Medical College has approved the protocol
and study (No. 01092010) dated 14.09.2010
3.2.4 Statistical Analysis
Data was analyzed using Pearson correlation and cross tabulations.
Chapter 4
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4. RESULTS AND DISCUSSION
4.1 Test Summary
A Total number of 70 patients with various thyroid disorders were included in
this study. Out of this 62 were women and 8 were men. The age of the patients ranged
from 13 years to 67 years with a mean age of 38 years.
Out of these patients, 8 had diffuse goiter, 60 had multinodular goiter and 2
had a solitary thyroid nodule at presentation
On the basis of size of the swelling the patients were graded into Grade I (5
Patients) Grade II (48 Patients) and Grade III (17 Patients)
 13 patients were hypothyroid, 27 were hyperthyroid and 30 were euthyroid.
The  patients  were  categorized  on  the  basis  of  histopathology  reports  35  had
nodular colloid goitre, 24 had thyroiditis, 3 patients had Graves disease, 6 had
papillary carcinoma and two had follicular adenoma
Among the patients with thyrotoxicosis, 9 had eye signs at presentation while
22 had tremors.
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TABLE – 1
CORRELATION OF ANTIBODIES TO VARIOUS THYROID ANTIGENS
WITH ANATOMICAL DIAGNOSIS
ANATOMICAL
DIAGNOSIS AMA ATG TSHRAb
Negative Positive Negative Positive Negative Positive
Diffuse Goiter
(n=8)
1 7 2 6 4 4
MNG (n=60) 10 50 19 41 35 25
SNT (n=2) 1 1 2 0 2 0
Among the patients with diffuse goitre, 7 were positive for AMA, 6 for ATG
and 4 for TSHRAb. Out of the 60 patients with MNG, 50 were positive from AMA,
41 for ATG, 25 for TSHRAb and 1 patient with solitary thyroid nodule was positive
for AMA. No patients with SNT were positive for ATG or TSHRAb (Table – 1)
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FIGURE – 1
CORRELATION OF ANTIBODIES TO VARIOUS THYROID ANTIGENS
WITH ANATOMICAL DIAGNOSIS
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TABLE – 2
CORRELATION OF SERUM LEVELS OF VARIOUS THYROID
ANTIBODIES WITH FUNCTIONAL STATES OF THYROID
Physiological
Diagnosis AMA ATG TSHRAb
Negative Positive Negative Positive Negative Positive
Hypothyroid
(n=13)
3 10 2 11 10 3
Hyperthyroid
(n=27)
1 26 5 22 5 22
Euthyroid (n=30) 8 22 16 14 26 4
Among the patients with hypothyroidism (n=13), 10 patients were positive for
AMA, 11 patients for ATG and 3 patients for TSHRAb. Among the hyperthyroid
(n=27), 26 patients were positive for AMA, 22 patients for ATG  and 22 patients for
TSHRAb. In Euthyroid patients (n=30), 22 patients had increased AMA, 14 patients
had increased ATG, and 4 were positive for THSRAb.(Table – 2)
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FIGURE – 2
CORRELATION OF SERUM LEVELS OF VARIOUS THYROID
ANTIBODIES WITH FUNCTIONAL STATES OF THYROID
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TABLE – 3
CORRELATION OF LEVELS OF ANTIBODIES WITH PATHOLOGICAL
DIAGNOSIS
Pathological
Diagnosis AMA ATG TSHRAb
Negative Positive Negative Positive Negative Positive
Nodular goiter
(n=35)
5 30 12 23 19 16
Thyroiditis (n=24) 3 21 6 18 15 9
Graves disease
(n=3)
0 3 0 3 0 3
Papillary
carcinoma (n=6)
3 3 3 3 5 1
Follicular adenoma
(n=2)
1 1 2 0 2 0
Among the nodular goitre (n=35) 30 were AMA positive and 23 were ATG
positive and 16 were TSHRAb positive. Among the thyroiditis (n=24) 21 were AMA
positive 18 were ATG positive and 9 were TSHRAb positive. In graves disease (n=3)
all were ATG, AMA and TSHRAb positive. In papillary carcinoma patients (n=6)
3were  both  ATG  and  AMA  positive  and  1  was  TSHRAb  positive.  In  follicular
neoplasm  (n=2)  1  was  AMA  positive  and  the  other  were  ATG  and  TSHRAb
negative.(Table – 3)
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FIGURE – 3
CORRELATION OF LEVELS OF THSRAb WITH PATHOLOGICAL
DIAGNOSIS
0
5
10
15
20
25
30
35
N
eg
at
iv
e
P
os
iti
ve
N
eg
at
iv
e
P
os
iti
ve
N
eg
at
iv
e
P
os
iti
ve
AMA ATG TSHRAb
Nodular goiter
(n=35)
Thyroiditis
(n=24)
Graves disease
(n=3)
Papillary
carcinoma
(n=6)
Follicular
35
TABLE – 4
MEAN AGE AND LEVELS OF THYROID HORMONES AND
THYROTROPIN IN TSHRAb POSITIVE PATIENTS
MEAN STD DEVIATION STD. ERROR
AGE 35.86 10.91 2.02
T3 213.35 145.01 26.92
T4 13.15 8.01 1.48
TSH 5.26 16.51 3.06
FT3 9.36 7.95 1.47
FT4 3.03 2.51 0.46
A total of 29 patients were positive for TSHR Ab in this study. The mean age
of these patients was 36 years. The mean value of T3 (Tri-iodothyrosine) was 213.35
ng/ml. The mean value of T4 (Total thyroxine) was 13.15 µg/dl. The mean value of
FT3 was 9.3 pg/ml. Mean value of FT4 was 30 ng/dl. The mean value of TSH
(thyrotropin) was 5.26 mIu/ml. (table – 4)
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TABLE - 5
CORRELATION OF THYROMEGALY WITH TSHRAb LEVELS
THYROMEGALY TSHRAbNEGATIVE
TSHRAb
POSITIVE TOTAL
GRADE I 5 0 5
GRADE II 27 21 48
GRADE III 9 8 17
TOTAL 41 29 70
None  of  the  patients  with  Grade  I  thyromegaly  had  elevated  levels  of
THSRAb. Out the 48 patients with Grade II thyromegaly, 21 were positive for
TSHRAb. Among 17 patients with Grade III thyromegaly, 8 patients had elevated
TSH receptor antibody. (Table 5)
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FIGURE - 4
CORRELATION OF THYROMEGALY WITH TSHRAb LEVELS
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TABLE - 6
CORRELATION OF MEAN VALUES OF VARIOUS ANTIBODIES WITH
THYROID FUNCTIONAL STATUS
N Mean Std. Deviation Std. Error
ATG 1 13 429.52 333.89 92.60
2 27 596.14 769.45 148.08
3 30 362.52 746.58 136.30
AMA 1 13 235.54 380.63 105.56
2 27 212.94 224.70 43.24
3 30 174.03 299.36 54.65
TSHrAb 1 13 1.94 4.907 1.36
2 27 20.33 16.12 3.10
3 30 .84 1.40 .25
NOTE 1-HYPOTHYROIDISM
2- HYPERTHYROIDISM
3- EUTHYROID
TSHR antibody levels were elevated in patients with hyperthyroidism (mean
value 20.33 IU ± 3.10). Mean TSHRAb levels in hypothyroid patients was 1.9 ± 1.3
and 0.8 ± 0.25 in euthyroid patients (Table 6)
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TABLE - 7
CORRELATION OF MEAN VALUES OF TSHRAb LEVELS WITH
PATHOLOGICAL DIAGNOSIS
N Mean Std. Deviation Std. Error
TSHrAb NODULAR GOITRE 35 8.04 13.16 2.22
THYROIDITIS 24 9.24 15.47 3.15
GRAVES DISEASE 3 17.75 6.15 3.55
PAPILLARY
CARCINOMA
6 7.00 16.16 6.59
FOLLICULAR
ADENOMA
2 .30 .00 .00
TSHRAb levels were high (17.7 ± 3.5) in patients with histopathological
diagnosis of Graves disease (Table -7)
In patients with pap ca (n=6) the one patient who had elevated TSHRAb had
clinical evidence of hyperthyroidism.
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FIGURE – 5
CORRELATION OF MEAN VALUES OF TSHRAb LEVELS WITH
PATHOLOGICAL DIAGNOSIS
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TABLE - 8
CORRELATION OF TSHRAb LEVELS WITH ATG AND AMA
TSHRAb
Negative
TSHRAb
Positive Total
TSHRAb only 5 2 7
TSHRAb + AMA 10 6 16
TSHRAb + ATG 5 0 5
TSHRAb + AMA + ATG 21 21 42
Total 41 29 70
Among the 70 patients 5 patients were negative for all the three abs-THSRAb,
AMA and ATG. 2 patients had elevation of only TSHRAb with normal ATG and
AMA levels. 10 patients had elevation of AMA only. 6 patients were positive for both
AMA and TSHRAb. 5 patients were positive for ATG only. None of the patients had
elevated TSH and ATG levels with normal AMA levels. 21 patients were Negative
for AMA,ATG and TSHRAb and 21 patients had elevated TSHRAb, AMA and ATG
levels.(Table – 8)
.
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FIGURE - 6
CORRELATION OF TSHRAb LEVELS WITH VARIOUS ANTIBODIES
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TABLE - 9
CORRELATION OF EYE SIGNS WITH TSHRAb LEVELS
TSHRAb AMA ATG
Positive Negative Positive Negative Positive Negative
Eye Sign (n=9) 8 1 9 0 7 2
Among the 9 patients with eye signs,  8 had elevated TSHRAb, out of which
one patient was hypothyroid.  All 9 patients had elevated AMA levels. Among the 22
patients with tremors, 19 had elevated TSHRAb (Table 9)
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TABLE - 10
PEARSON CORRELATION OF SAP AND SERUM CALCIUM WITH
TSHRAb, AMA AND ATG LEVELS
TSHrAb CALCIUM SAP
ATG Pearson Correlation .082 -.342** .159
Sig. (2-tailed) .501 .004 .189
N 70 70 70
AMA Pearson Correlation .035 -.222 .153
Sig. (2-tailed) .773 .064 .207
N 70 70 70
TSHrAb Pearson Correlation 1 -.052 .335**
Sig. (2-tailed) .667 .005
N 70 70 70
**. Correlation is significant at the 0.01 level (2-tailed).
*. Correlation is significant at the 0.05 level (2-tailed).
When Ca and SAP levels were correlated with hyperthyroidism, eye signs,
tremors and TSHRAbs and histo-pathological diagnosis of Graves’ disease, SAP was
elevated in patients with hyperthyroidism, tremors, eye sign and elevated TSHRAb
and Graves’ pathology.  Elevated Ca levels correlated with elevated ATG levels. Ca
levels did not correlate with any of these entities. (Table 10)
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4.5 DISCUSSION
TSHRAb is a useful diagnostic tool for diagnosis of Graves’ disease.
The prevalence of TSHRAb in hyperthyroid and Graves disease is 70-100 %
In  the  present  study  all  the  patients  with  histopathological  diagnosis  of
Graves’ disease were positive for TSHRAb (Prevalence 100 %)
Though presence3 of TSHRAb is specific for Graves’ disease, some studies
show the TSHRAb positivity present in significant proportion of toxic MNG.13
In the present study, TSHRAb positivity was seen in 26.05 % of patients
(16 patients out of 60).
It is a common observation that the level of TSHRAb grossly parallels the
degree of hyperthyroidism as assessed by serum levels of thyroid hormones.38,39
In the present study also, the mean value of TSHRAb was significantly higher
in patients with hyperthyroidism (20.33 IU ± 3.10). So, TSHRAb levels may be taken
as a marker of severity of the disease.
In  general,  good  agreement  has  been  observed  with  TSHRAb  levels  and
thyroid volume.40 Rieu and co workers15 found that the volume of both hyperplastic
and nodular goiter correlated with TSHRAb levels, confirming the growth stimulation
potential of these antibodies on thyroid tissue.
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In the present study, TSHRAb levels were significantly higher in patients with
Grade II and Grade III thyromegaly.
TSHRAb assay is very specific and sensitive for hyperthyroid Graves’ disease.
Up to 98% of untreated patients are positive for TSHRAbs with very few false-
positive results.41
In the present study, all the 3 patients who had histo-pathological diagnosis of
Graves’  disease  had  elevated  TSHRAb  levels.  3  patients  who  were  hypo-thyroid
(out of 13) were positive for TSHRAbs, probably indicating false-positive results.
Hypothyroid Graves’ disease is defined as development of Graves’
ophthalmopathy in hypothyroid subjects. The association of infiltrative
ophthalmopathy with hypothyroidism is rare.37 In these patients, TSHRAb assay
confirms the association of Graves’ disease with autoimmune thyroiditis.
Out  of  the  patients  with  eye  signs  in  the  present  study,  one  patient  had
hypothyroidism. The elevated TSHRAb levels in this patient indicates co-existence of
autoimmune thyroiditis with Graves’ disease.
Clinical sign sand symptoms of ophthalmopathy are present in about 50% of
the patients with Graves’ disease.42, 43 In the present study, all three patients with
histopathological diagnosis of Graves’ disease had eye disease and elevated TSHRAb
levels.
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In some studies, the level of TSHR gene expression was found to be higher in
the orbital tissue of patients with Graves’ ophthalmopathy when compared with
normal orbital tissues or tissue from patients with inactive eye disease.44,45,46  In the
present study, out of 9 patients with ophthalmopathy, 8 patients had elevated
TSHRAb levels as well. This may indicate active orbital autoimmune response.
When  present,  the  Graves’  ophthalmopathy  coincides  with  the  onset  of
thyrotoxicosis in about 40% of cases, follows in another 40% of case and precedes
onset of thyrotoxicosis in 20%.47,48 Even when the onset of the two disorders doesn’t
coincide, each occurs within 18 months from the onset of the first manifestation.
In the present study, one patient with ophthalmopathy who was negative for
TSHRAbs might have developed the eye disease before the onset of thyrotoxicosis.
Antithyroid antibodies in serum should be determined routinely in the work-up
of the patients with multinodular goiter. This recommendation is based mainly on the
fact that Hashimoto’s thyroiditis may be mistaken for simple multinodular goiter and
that these antibodies may be recognized as increased risk for 131I-induced
hypo-thyroidism as well as Graves’ disease.49
In the present study, out of 60 patients with multinodular goiter 25 had
increased  TSHRAb  levels.  Had  TSHRAb  estimation  not  been  done,  possibility  of
Hashimoto’s thyroiditis and Graves’ disease might have been missed.
Thyroid carcinoma occurs with higher-than-expected frequency (4% - 7%)
and greater severity in patients with Greaves’ disease. TSHRAb can stimulate the
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function and growth of differentiated thyroid cancer metastases and angiogenesis in
the thyroid. In a recent publication, among 21 patients with thyroid carcinoma in
Graves’ disease, TSHRAbs were positive in all but one of the patients in whom,
recurrence developed.28
In the present study, out of 6 patients with papillary carcinoma, TSHRAbs
were elevated in one patient, who had clinical and biochemical evidence of
hyper-thyroidism and who later turned out to have inoperable metastatic disease.
Hyperthyroid Graves’ disease is usually more severe in younger patients.
Long-term remission rates in children and adolescents are usually less than 30%-40%
and much lower in pre-pubertal age (17%).26 The  low  remission  rate  and  the
uncertainty regarding anti-thyroid drug treatment in this age-group support the use of
any method capable of identifying patients who will benefit from radical treatment.
The predictive significance of the new-generation assays of TSHRAb is expected to
be even more pertinent in children and adolescents than in adults.
In the present study, 3 children who were in pre-pubertal age-group were
found to have increased TSHRAb levels with toxicity. These patients are candidates
who require treatment in the form of total thyroidectomy.
IN the present study, levels of serum Alkaline phosphatase correlated with
hyperthyroidism, tremors, eye sign and elevated TSHRAb and Graves’ pathology.
Assays for TSHRAb should not be considered a magic tool for the
management of autoimmune thyroid disease, but as one indicator among others
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(e.g. thyroid volume, basal TSH, etc.) in a complex and multifactorial situation. The
contribution of TSHRAb assays to the prediction of post-treatment outcome is
significant but limited. Such assays are useful in clinical practice when the risks of the
wrong therapeutic decision are significant. More informative is the longitudinal study
of TSHRAb levels when compared with a single, end-of-treatment determination.
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5.  CONCLUSION
? TSHRAb is a useful diagnostic tool for diagnosis of Graves’ disease.
? Though it has been considered to be specific for Graves’ disease, increased
levels were found in patients with multinodular goiter. Estimation of anti-
thyroid antibodies in patients with multinodular goiter is highly
recommended to recognize the association of autoimmune thyroiditis and
Graves’ disease in multinodular goiter.
? The levels of TSHRAb grossly parallel the degree of hyperthyroidism and
the grade of thyromegaly.
? Elevated TSHRAb levels in patients with ophthalmopathy indicate active
eye disease. In euthyroid patients with ophthalmopathy, increased levels of
TSHRAb may predict the future occurrence of Graves’ disease. In patients
with elevated levels of TSHRAb, AMA and ATG, the risk of development
of eye signs is significantly higher.
? Elevated levels of TSHRAbs in patients with papillary carcinoma indicates
poor prognosis.
? Level of Alkaline phosphatase in serum correlates with serum levels of
TSHRAb and severity of disease. So elevated levels of Serum Alkaline
phosphatase along with TSHRAb in hyperthyroidism may be taken as a
marker for severity of Graves’ disease.
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